O n Monday, Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), currently trading at $13.39, after an incident involving a potential news leak. According to ...

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for ORIC Pharmaceuticals in a report ...

Cantor Fitzgerald notes that the firm discovered ... the high-level news commentary “sounds very positive” for mevrometostat and Oric Pharmaceuticals (ORIC). The firm has an Overweight ...

ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report) is expected to post its quarterly earnings results before the market ...

On Tuesday, Cantor Fitzgerald reiterated its confidence in ORIC Pharmaceuticals (NASDAQ:ORIC), maintaining an Overweight stock rating. Trading at $11.49, ORIC has seen analyst targets ranging from $13 ...

The Central Bank has fined the Irish unit of US investment group Cantor Fitzgerald €452,790 for failing to report suspicious transactions that may have indicated market abuse. Between March 2017 ...

WASHINGTON (Reuters) -The U.S. Senate voted on Tuesday 51-45 to confirm President Donald Trump's nominee Howard Lutnick, the billionaire chairman and CEO of Wall Street firm Cantor Fitzgerald ...

On Monday, Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), currently trading at $13.39, after an incident involving a potential news leak. According to ...